BACKGROUND AND PURPOSE: Glucocorticoid-induced osteoporosis (GIO) is the leading cause of secondary osteoporosis. Clinical evidence suggests a role for genistein aglycone in the treatment of post-menopausal osteopenia although proof of efficacy in comparison with currently available treatments is still lacking. To clarify this issue, we investigated the effects of genistein on bone compared with alendronate in experimental GIO. EXPERIMENTAL APPROACH: A total of 28 female Sprague-Dawley rats were used. GIO was induced by daily injections of methylprednisolone (MP; 30 mg x kg(-1) s.c.) for 60 days. Sham GIO animals (Sham-MP) were injected daily with the MP vehicle. At the end of the osteoporosis development period, MP rats were randomized to receive: vehicle (n= 7), genistein aglycone (5 mg x kg(-1) s.c.; n= 7) or alendronate (0.03 mg x kg(-1) s.c.; n= 7). Treatment lasted 60 days. Sham-MP animals were treated with vehicle for an additional 60 days. At the beginning and at the end of treatments, animals were examined for bone mineral density and bone mineral content. Bone-alkaline phosphatase and carboxy-terminal collagen cross links were determined; femurs were removed and tested for breaking strength and histology. KEY RESULTS: Genistein aglycone showed a greater increase in bone mineral density, bone mineral content and in breaking strength than alendronate and significantly increased bone-alkaline phosphatase (bone formation marker), reduced carboxy-terminal collagen cross links (bone resorption marker), compared with alendronate. Both treatments improved bone histology and the histological score. CONCLUSION AND IMPLICATIONS: The results strongly suggest that the genistein aglycone might be an alternative therapy for the management of secondary osteoporosis.
BACKGROUND AND PURPOSE: Glucocorticoid-induced osteoporosis (GIO) is the leading cause of secondary osteoporosis. Clinical evidence suggests a role for genistein aglycone in the treatment of post-menopausal osteopenia although proof of efficacy in comparison with currently available treatments is still lacking. To clarify this issue, we investigated the effects of genistein on bone compared with alendronate in experimental GIO. EXPERIMENTAL APPROACH: A total of 28 female Sprague-Dawley rats were used. GIO was induced by daily injections of methylprednisolone (MP; 30 mg x kg(-1) s.c.) for 60 days. Sham GIO animals (Sham-MP) were injected daily with the MP vehicle. At the end of the osteoporosis development period, MPrats were randomized to receive: vehicle (n= 7), genistein aglycone (5 mg x kg(-1) s.c.; n= 7) or alendronate (0.03 mg x kg(-1) s.c.; n= 7). Treatment lasted 60 days. Sham-MP animals were treated with vehicle for an additional 60 days. At the beginning and at the end of treatments, animals were examined for bone mineral density and bone mineral content. Bone-alkaline phosphatase and carboxy-terminal collagen cross links were determined; femurs were removed and tested for breaking strength and histology. KEY RESULTS:Genistein aglycone showed a greater increase in bone mineral density, bone mineral content and in breaking strength than alendronate and significantly increased bone-alkaline phosphatase (bone formation marker), reduced carboxy-terminal collagen cross links (bone resorption marker), compared with alendronate. Both treatments improved bone histology and the histological score. CONCLUSION AND IMPLICATIONS: The results strongly suggest that the genistein aglycone might be an alternative therapy for the management of secondary osteoporosis.
Authors: J D Adachi; K G Saag; P D Delmas; U A Liberman; R D Emkey; E Seeman; N E Lane; J M Kaufman; P E Poubelle; F Hawkins; R Correa-Rotter; C J Menkes; J A Rodriguez-Portales; T J Schnitzer; J A Block; J Wing; H H McIlwain; R Westhovens; J Brown; J A Melo-Gomes; B L Gruber; M J Yanover; M O Leite; K G Siminoski; M C Nevitt; J T Sharp; M P Malice; T Dumortier; M Czachur; W Carofano; A Daifotis Journal: Arthritis Rheum Date: 2001-01
Authors: Robert S Weinstein; Jin-Ran Chen; Cara C Powers; Scott A Stewart; Reid D Landes; Teresita Bellido; Robert L Jilka; A Michael Parfitt; Stavros C Manolagas Journal: J Clin Invest Date: 2002-04 Impact factor: 14.808
Authors: Mark S Cooper; Elizabeth H Rabbitt; Philippa E Goddard; William A Bartlett; Martin Hewison; Paul M Stewart Journal: J Bone Miner Res Date: 2002-06 Impact factor: 6.741
Authors: A Bitto; B P Burnett; F Polito; H Marini; R M Levy; M A Armbruster; L Minutoli; V Di Stefano; N Irrera; S Antoci; R Granese; F Squadrito; D Altavilla Journal: Br J Pharmacol Date: 2008-08-11 Impact factor: 8.739
Authors: H Marini; F Polito; D Altavilla; N Irrera; L Minutoli; M Calò; E B Adamo; M Vaccaro; F Squadrito; A Bitto Journal: Br J Pharmacol Date: 2010-07 Impact factor: 8.739
Authors: Christian Heiss; Parameswari Govindarajan; Gudrun Schlewitz; Nasr Y A Hemdan; Nathalie Schliefke; Volker Alt; Ulrich Thormann; Katrin Susanne Lips; Sabine Wenisch; Alexander C Langheinrich; Daniel Zahner; Reinhard Schnettler Journal: Med Sci Monit Date: 2012-06